Kumar Nadhan, MD
Dermatology · Monterey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 6 carriers
- Office
- 1
- Since medical school
- 8 years
- Temple University School of Medicine, 2018
Offices
1 location · Csi Medical Group · 104 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
22 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nadhan’s office at (831) 333-9008 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Oct 29, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Oct 29, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Oct 29, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A191911 · Current
Licensed to practise in California · since 2023 · expires 2027-11-30 · Lewis Katz School of Medicine at Temple University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$145,006
Medicare paid this office $145,006 for 866 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 550 | $43,689 | $62 |
| Destruction of skin growth, 1-14 growths | 214 | $21,660 | $89 |
| Destruction of precancer skin growth, 1 growth | 359 | $16,756 | $42 |
| Return visit (30+ min) | 117 | $15,435 | $102 |
| Biopsy of related skin growth, first growth | 123 | $9,376 | $74 |
See all 15 services
| Short return visit (20+ min) | 550 | $43,689 | $62 |
| Destruction of skin growth, 1-14 growths | 214 | $21,660 | $89 |
| Destruction of precancer skin growth, 1 growth | 359 | $16,756 | $42 |
| Return visit (30+ min) | 117 | $15,435 | $102 |
| Biopsy of related skin growth, first growth | 123 | $9,376 | $74 |
| New patient visit (30+ min) | 108 | $7,677 | $71 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 21 | $6,993 | None |
| Destruction of precancer skin growth, 2-14 growths | 253 | $5,263 | $5 |
| Short return visit | 111 | $4,722 | $40 |
| Application of light to destroy precancer skin growth | 21 | $2,238 | $102 |
| New patient visit (45+ min) | 19 | $1,797 | $95 |
| Injection into skin growth, 1-7 growths | 28 | $1,580 | $44 |
| New patient visit (15+ min) | 29 | $1,296 | $45 |
| Biopsy of related skin growth, each additional growth | 17 | $771 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 38 | $68 | None |
Procedures Medicare counted
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 1706 | More than 97% of doctors who do this |
| Removal or shaving of skin growth | 16 | More than 69% of doctors who do this |
| Skin biopsy | 159 | More than 82% of doctors who do this |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | – | 978 |
| Destruction of precancer skin growth, 1 growth | – | 399 |
| Destruction of skin growth, 1-14 growths | – | 244 |
| Biopsy of related skin growth, first growth | – | 126 |
| Injection into skin growth, 1-7 growths | – | 36 |
| Biopsy of related skin growth, each additional growth | – | 18 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
866 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 13% · Women 50% · Also on Medicaid 13% · Health risk score 1.00. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Coronary heart disease 26% · Diabetes 17% · Chronic kidney disease 17% · Cancer 17% · Atrial fibrillation 16% · Depression 15% · Heart failure 12% · COPD 12% · Dementia 6% · Stroke 6%.
The office billed $383,325, Medicare allowed $218,601 and paid $145,006; for 3,153 services of 41 kinds; $7,061 of it was for drugs given in the office and $137,945 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 866 | 3,153 | 76 | 1.00 | $383,325 | $145,006 |
| 2023 | 34 | 66 | 74 | 0.81 | $10,145 | $4,611 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Short return visit (20+ min) | 21 | $1,614 | $77 |
Medicaid work
$192 in 2024
Medicaid paid $192 for 40 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 40 | $192 |
| 2024 | 40 | 1 | 22 | $192 |
Drugs they prescribed that Part D paid
$91,365
Pharmacies billed $91,365 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,340) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,297 generic and 43 brand-name prescriptions · $91,365 in drug cost · 102 antibiotic prescriptions to 62 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tacrolimus | 45 | $5,105 | $113 |
| Clobetasol Propionate | 105 | $4,784 | $46 |
| Fluorouracil | 73 | $4,352 | $60 |
| Ketoconazole | 200 | $3,111 | $16 |
| Fluocinonide | 87 | $2,850 | $33 |
See all 26 drugs
| Tacrolimus | 45 | $5,105 | $113 |
| Clobetasol Propionate | 105 | $4,784 | $46 |
| Fluorouracil | 73 | $4,352 | $60 |
| Ketoconazole | 200 | $3,111 | $16 |
| Fluocinonide | 87 | $2,850 | $33 |
| Metronidazole | 45 | $2,167 | $48 |
| Triamcinolone Acetonide | 178 | $2,051 | $12 |
| Doxycycline Hyclate | 73 | $1,451 | $20 |
| Desonide | 38 | $1,434 | $38 |
| Ciclopirox | 20 | $603 | $30 |
| Imiquimod | 28 | $574 | $21 |
| Clindamycin Phosphate | 18 | $558 | $31 |
| Tretinoin | 11 | $514 | $47 |
| Valsartan-Hydrochlorothiazide | 12 | $489 | $41 |
| Doxycycline Monohydrate | 15 | $343 | $23 |
| Gentamicin Sulfate | 12 | $343 | $29 |
| Nystatin-Triamcinolone | 13 | $327 | $25 |
| Fluconazole | 36 | $309 | $9 |
| Mupirocin | 34 | $267 | $8 |
| Hydrocortisone | 43 | $214 | $5 |
| Allopurinol | 12 | $181 | $15 |
| Carvedilol | 12 | $151 | $13 |
| Atorvastatin | 12 | $148 | $12 |
| Omeprazole | 12 | $134 | $11 |
| Gabapentin | 12 | $104 | $9 |
| Minoxidil | 12 | $40 | $3 |
Year by year
| 2024 | 1,340 | 503 | 0% (0) | 3% | $91,365 |
| 2023 | 118 | 48 | 0% (0) | 21% | $33,742 |
| 2022 | 156 | 57 | 0% (0) | 17% | $7,578 |
| 2021 | 190 | 61 | 0% (0) | 17% | $72,879 |
| 2020 | 41 | 26 | 0% (0) | 0% | $1,596 |
| 2019 | 43 | 19 | 0% (0) | None | $4,651 |
| 2018 | 27 | 15 | 0% (0) | None | $888 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Clobetasol Propionate | 13 | $1,168 | $90 |
| Fluocinonide | 12 | $766 | $64 |
| Triamcinolone Acetonide | 28 | $408 | $15 |
| Hydrocortisone | 11 | $60 | $5 |
| Humira | 11 | $6 | $1 |
2022: 4 drugs
| Clobetasol Propionate | 23 | $2,449 | $106 |
| Fluocinonide | 11 | $671 | $61 |
| Triamcinolone Acetonide | 36 | $537 | $15 |
| Humira | 12 | $6 | $1 |
2021: 5 drugs
| Dupixent | 12 | $40,842 | $3,404 |
| Humira | 12 | $26,130 | $2,178 |
| Triamcinolone Acetonide | 45 | $888 | $20 |
| Fluocinonide | 13 | $705 | $54 |
| Doxycycline Hyclate | 14 | $362 | $26 |
Money from drug and device companies
$5,929 in 2025
| 2025 | 19 | 198 | None | $5,929 |
| 2024 | 16 | 93 | None | $2,543 |
| 2023 | 4 | 5 | None | $146 |
| 2022 | 4 | 9 | None | $279 |
| 2021 | 3 | 4 | None | $82 |
| 2020 | 3 | 6 | None | $121 |
| 2019 | 1 | 3 | None | $41 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Incyte | Opzelura | $746 | 25 payments
|
| Genzyme | Dupixent | $634 | 13 payments
|
| Galderma Laboratories L.P. | Nemluvio | $623 | 13 payments
|
| LEO Pharma | Anzupgo | $611 | 26 payments
|
| Pfizer | Cibinqo | $593 | 21 payments
|
| Abbvie | Skyrizi | $571 | 27 payments
|
See all 197 published payments
| Genzyme | Meals · 2025-12-19 | Dupixent | $25 |
| Incyte | Meals · 2025-12-17 | Opzelura | $29 |
| Arcutis Biotherapeutics | Meals · 2025-12-17 | Zoryve | $28 |
| Genzyme | Meals · 2025-12-16 | Dupixent | $120 |
| Abbvie | Meals · 2025-12-11 | Rinvoq | $31 |
| Pfizer | Meals · 2025-12-11 | Cibinqo | $7 |
| Abbvie | Meals · 2025-12-10 | Skyrizi | $25 |
| Galderma Laboratories L.P. | Meals · 2025-12-10 | Nemluvio | $142 |
| LEO Pharma | Meals · 2025-12-09 | Adbry | $14 |
| LEO Pharma | Meals · 2025-12-09 | Adbry | $14 |
| Incyte | Meals · 2025-12-05 | Opzelura | $30 |
| Novartis Pharmaceuticals | Meals · 2025-12-04 | Rhapsido | $25 |
| Pfizer | Meals · 2025-12-04 | Cibinqo | $24 |
| Arcutis Biotherapeutics | Meals · 2025-12-03 | Zoryve | $24 |
| Abbvie | Meals · 2025-12-02 | Skyrizi | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-12-02 | Dupixent | $30 |
| Pfizer | Meals · 2025-11-22 | Litfulo | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-11-20 | Dupixent | $114 |
| Incyte | Meals · 2025-11-20 | Opzelura | $19 |
| Pfizer | Meals · 2025-11-20 | Cibinqo | $14 |
| Pfizer | Meals · 2025-11-19 | Cibinqo | $148 |
| LEO Pharma | Meals · 2025-11-19 | Anzupgo | $5 |
| LEO Pharma | Meals · 2025-11-19 | Anzupgo | $5 |
| Abbvie | Meals · 2025-11-18 | Rinvoq | $29 |
| Journey Medical | Meals · 2025-11-18 | None | $16 |
| LEO Pharma | Meals · 2025-11-18 | Anzupgo | $4 |
| LEO Pharma | Meals · 2025-11-17 | Adbry | $14 |
| Incyte | Meals · 2025-11-15 | Opzelura | $22 |
| Incyte | Meals · 2025-11-14 | Opzelura | $21 |
| Arcutis Biotherapeutics | Meals · 2025-11-12 | Zoryve | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-10 | Cosentyx | $29 |
| Galderma Laboratories L.P. | Meals · 2025-11-08 | Nemluvio | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-07 | Sotyktu | $29 |
| Journey Medical | Meals · 2025-11-07 | None | $30 |
| Incyte | Meals · 2025-11-06 | Opzelura | $28 |
| LEO Pharma | Meals · 2025-11-06 | Adbry | $11 |
| Cipher Pharmaceuticals US | Meals · 2025-10-30 | Natroba | $27 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $27 |
| Abbvie | Meals · 2025-10-28 | Rinvoq | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-27 | Sotyktu | $20 |
| Pfizer | Meals · 2025-10-25 | Litfulo | $30 |
| Abbvie | Meals · 2025-10-23 | Skyrizi | $15 |
| Genzyme | Meals · 2025-10-23 | Dupixent | $33 |
| Ucb | Meals · 2025-10-22 | Bimzelx | $3 |
| Ucb | Meals · 2025-10-22 | Bimzelx | $26 |
| Arcutis Biotherapeutics | Meals · 2025-10-22 | Zoryve | $141 |
| LEO Pharma | Meals · 2025-10-21 | Adbry | $9 |
| Arcutis Biotherapeutics | Meals · 2025-10-21 | Zoryve | $12 |
| Genzyme | Meals · 2025-10-17 | Dupixent | $37 |
| Galderma Laboratories L.P. | Meals · 2025-10-16 | Nemluvio | $18 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | Rhapsido | $29 |
| Lilly USA | Meals · 2025-10-08 | Taltz | $33 |
| Sun Pharmaceutical Industries | Meals · 2025-10-08 | Winlevi | $138 |
| Pfizer | Meals · 2025-10-04 | Litfulo | $25 |
| Incyte | Meals · 2025-10-03 | Opzelura | $20 |
| Incyte | Meals · 2025-10-03 | Opzelura | $21 |
| LEO Pharma | Meals · 2025-10-03 | Anzupgo | $6 |
| LEO Pharma | Meals · 2025-10-03 | Anzupgo | $145 |
| Pfizer | Meals · 2025-10-01 | Cibinqo | $22 |
| Galderma Laboratories L.P. | Meals · 2025-09-24 | Nemluvio | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-22 | Sotyktu | $21 |
| Ucb | Meals · 2025-09-19 | Bimzelx | $23 |
| LEO Pharma | Meals · 2025-09-19 | Adbry | $10 |
| Abbvie | Meals · 2025-09-18 | Skyrizi | $26 |
| Ucb | Meals · 2025-09-17 | Bimzelx | $6 |
| Ucb | Meals · 2025-09-17 | Bimzelx | $20 |
| LEO Pharma | Meals · 2025-09-17 | Adbry | $9 |
| Arcutis Biotherapeutics | Meals · 2025-09-12 | Zoryve | $14 |
| Lilly USA | Meals · 2025-09-11 | Taltz | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-09-10 | Libtayo | $33 |
| Incyte | Meals · 2025-09-06 | Opzelura | $26 |
| Incyte | Meals · 2025-09-05 | Opzelura | $27 |
| Janssen Biotech | Meals · 2025-09-03 | Tremfya | $14 |
| Galderma Laboratories L.P. | Meals · 2025-09-03 | Nemluvio | $33 |
| Incyte | Meals · 2025-08-27 | Opzelura | $8 |
| Galderma Laboratories L.P. | Meals · 2025-08-23 | Nemluvio | $41 |
| Incyte | Meals · 2025-08-22 | Opzelura | $30 |
| Abbvie | Meals · 2025-08-20 | Rinvoq | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-08-20 | Dupixent | $15 |
| Arcutis Biotherapeutics | Meals · 2025-08-19 | Zoryve | $28 |
| Ucb | Meals · 2025-08-14 | Bimzelx | $26 |
| Abbvie | Meals · 2025-08-13 | Skyrizi | $15 |
| Incyte | Meals · 2025-08-13 | Opzelura | $28 |
| Pfizer | Meals · 2025-08-13 | Cibinqo | $13 |
| Genzyme | Meals · 2025-08-13 | Dupixent | $80 |
| Lilly USA | Meals · 2025-08-12 | Taltz | $22 |
| Lilly USA | Meals · 2025-08-08 | Taltz | $15 |
| Genzyme | Meals · 2025-08-08 | Dupixent | $26 |
| Arcutis Biotherapeutics | Meals · 2025-08-05 | Zoryve | $30 |
| LEO Pharma | Meals · 2025-07-25 | Adbry | $27 |
| Organon | Meals · 2025-07-24 | Vtama | $188 |
| Organon | Meals · 2025-07-23 | Vtama | $31 |
| Abbvie | Meals · 2025-07-22 | Rinvoq | $27 |
| LEO Pharma | Meals · 2025-07-22 | Anzupgo | $146 |
| Ucb | Meals · 2025-07-18 | Bimzelx | $30 |
| Incyte | Meals · 2025-07-18 | Opzelura | $23 |
| Pfizer | Meals · 2025-07-18 | Litfulo | $25 |
| Galderma Laboratories L.P. | Meals · 2025-07-18 | None | $23 |
| Lilly USA | Meals · 2025-07-16 | Taltz | $30 |
| Lilly USA | Meals · 2025-07-11 | Taltz | $24 |
| Arcutis Biotherapeutics | Meals · 2025-07-11 | Zoryve | $12 |
| Arcutis Biotherapeutics | Meals · 2025-07-11 | Zoryve | $11 |
| Incyte | Meals · 2025-07-04 | Opzelura | $28 |
| Genzyme | Meals · 2025-07-02 | Dupixent | $35 |
| Pfizer | Meals · 2025-07-01 | Cibinqo | $27 |
| Galderma Laboratories L.P. | Meals · 2025-06-27 | Nemluvio | $26 |
| Abbvie | Meals · 2025-06-25 | Rinvoq | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-06-21 | Dupixent | $20 |
| Arcutis Biotherapeutics | Meals · 2025-06-18 | Zoryve | $25 |
| Incyte | Meals · 2025-06-17 | Opzelura | $17 |
| LEO Pharma | Meals · 2025-06-17 | Adbry | $17 |
| Abbvie | Meals · 2025-06-12 | Skyrizi | $23 |
| Abbvie | Education · 2025-06-12 | Skyrizi | $10 |
| Incyte | Meals · 2025-06-09 | Opzelura | $113 |
| Incyte | Meals · 2025-06-07 | Opzelura | $30 |
| Lilly USA | Meals · 2025-06-04 | Taltz | $29 |
| Genzyme | Meals · 2025-06-03 | Dupixent | $21 |
| LEO Pharma | Meals · 2025-06-02 | Adbry | $14 |
| Arcutis Biotherapeutics | Meals · 2025-05-27 | Zoryve | $3 |
| Sun Pharmaceutical Industries | Meals · 2025-05-23 | Winlevi | $20 |
| Lilly USA | Meals · 2025-05-22 | Taltz | $32 |
| Arcutis Biotherapeutics | Meals · 2025-05-22 | Zoryve | $6 |
| Pfizer | Meals · 2025-05-21 | Cibinqo | $29 |
| Pfizer | Meals · 2025-05-21 | Cibinqo | $12 |
| Incyte | Meals · 2025-05-17 | Opzelura | $30 |
| Ucb | Meals · 2025-05-16 | Bimzelx | $0 |
| Ucb | Meals · 2025-05-16 | Bimzelx | $33 |
| LEO Pharma | Meals · 2025-05-16 | Adbry | $17 |
| Pfizer | Meals · 2025-05-09 | Litfulo | $29 |
| Lilly USA | Meals · 2025-05-07 | Taltz | $27 |
| Abbvie | Meals · 2025-05-06 | Rinvoq | $6 |
| Amgen | Meals · 2025-05-06 | Otezla | $49 |
| Genzyme | Meals · 2025-05-06 | Dupixent | $31 |
| Incyte | Meals · 2025-05-02 | Opzelura | $28 |
| Abbvie | Meals · 2025-05-01 | Rinvoq | $8 |
| Abbvie | Meals · 2025-05-01 | Rinvoq | $22 |
| Incyte | Meals · 2025-05-01 | Opzelura | $123 |
| LEO Pharma | Meals · 2025-05-01 | Adbry | $8 |
| Lilly USA | Meals · 2025-04-29 | Taltz | $32 |
| Ucb | Meals · 2025-04-25 | Bimzelx | $7 |
| Pfizer | Meals · 2025-04-18 | Litfulo | $29 |
| LEO Pharma | Meals · 2025-04-18 | Adbry | $23 |
| Pfizer | Meals · 2025-04-17 | Cibinqo | $20 |
| Pfizer | Meals · 2025-04-17 | Cibinqo | $18 |
| Galderma Laboratories L.P. | Meals · 2025-04-17 | Nemluvio | $34 |
| Abbvie | Meals · 2025-04-16 | Rinvoq | $3 |
| LEO Pharma | Meals · 2025-04-14 | Adbry | $28 |
| Arcutis Biotherapeutics | Meals · 2025-04-09 | Zoryve | $24 |
| Ucb | Meals · 2025-04-08 | Bimzelx | $32 |
| LEO Pharma | Meals · 2025-04-04 | Adbry | $19 |
| Abbvie | Meals · 2025-04-03 | Skyrizi | $28 |
| Genzyme | Meals · 2025-04-02 | Dupixent | $33 |
| Pfizer | Meals · 2025-03-25 | Cibinqo | $29 |
| Lilly USA | Meals · 2025-03-21 | Taltz | $30 |
| Galderma Laboratories L.P. | Meals · 2025-03-21 | Nemluvio | $15 |
| Genentech USA | Meals · 2025-03-20 | Xolair | $31 |
| LEO Pharma | Meals · 2025-03-19 | Adbry | $22 |
| Organon | Meals · 2025-03-15 | Vtama | $30 |
| Incyte | Meals · 2025-03-14 | Opzelura | $6 |
| Incyte | Meals · 2025-03-14 | Opzelura | $6 |
| Incyte | Meals · 2025-03-14 | Opzelura | $4 |
| Lilly USA | Meals · 2025-03-12 | Taltz | $31 |
| Abbvie | Meals · 2025-03-12 | Skyrizi | $21 |
| LEO Pharma | Meals · 2025-03-12 | Adbry | $8 |
| Genzyme | Meals · 2025-03-11 | Dupixent | $37 |
| Abbvie | Meals · 2025-03-07 | Skyrizi | $20 |
| Amgen | Meals · 2025-03-07 | Otezla | $19 |
| Pfizer | Meals · 2025-03-07 | Cibinqo | $25 |
| Abbvie | Meals · 2025-02-27 | Skyrizi | $25 |
| Genzyme | Meals · 2025-02-21 | Dupixent | $29 |
| Abbvie | Meals · 2025-02-20 | Skyrizi | $15 |
| Amgen | Meals · 2025-02-18 | Otezla | $29 |
| Lilly USA | Meals · 2025-02-12 | Taltz | $30 |
| Pfizer | Meals · 2025-02-08 | Litfulo | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-02-07 | Dupixent | $16 |
| Pfizer | Meals · 2025-02-07 | Cibinqo | $16 |
| Incyte | Meals · 2025-02-06 | Opzelura | $28 |
| Galderma Laboratories L.P. | Meals · 2025-02-05 | Nemluvio | $109 |
| Regeneron Healthcare Solutions | Meals · 2025-01-30 | Libtayo | $34 |
| Lilly USA | Meals · 2025-01-29 | Taltz | $26 |
| Galderma Laboratories L.P. | Meals · 2025-01-29 | Nemluvio | $13 |
| Genentech USA | Meals · 2025-01-28 | Xolair | $24 |
| Arcutis Biotherapeutics | Meals · 2025-01-27 | Zoryve | $21 |
| Abbvie | Meals · 2025-01-24 | Skyrizi | $12 |
| LEO Pharma | Meals · 2025-01-24 | Adbry | $19 |
| Abbvie | Meals · 2025-01-22 | Rinvoq | $31 |
| LEO Pharma | Meals · 2025-01-22 | Adbry | $8 |
| Lilly USA | Meals · 2025-01-18 | Taltz | $4 |
| Lilly USA | Meals · 2025-01-18 | Taltz | $28 |
| Abbvie | Meals · 2025-01-17 | Skyrizi | $31 |
| Genzyme | Meals · 2025-01-16 | Dupixent | $128 |
| Arcutis Biotherapeutics | Meals · 2025-01-16 | Zoryve | $27 |
| LEO Pharma | Meals · 2025-01-10 | Adbry | $10 |
| Lilly USA | Meals · 2025-01-08 | Taltz | $27 |
| Lilly USA | Meals · 2025-01-08 | Taltz | $2 |
| Abbvie | Meals · 2025-01-08 | Rinvoq | $31 |
| Galderma Laboratories L.P. | Meals · 2025-01-06 | Nemluvio | $123 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,543
| Abbvie | Skyrizi | $760 | 25 payments
|
| LEO Pharma | Adbry | $405 | 15 payments
|
| Incyte | Opzelura | $323 | 13 payments
|
| Galderma Laboratories L.P. | None | $210 | 11 payments
|
| Genzyme | Dupixent | $182 | 3 payments
|
| Lilly USA | Taltz | $169 | 6 payments
|
| Novartis Pharmaceuticals | Xolair | $90 | 3 payments
|
| Sun Pharmaceutical Industries | Ilumya | $86 | 3 payments
|
| Ucb | Bimzelx | $71 | 3 payments
|
| Dermavant Sciences | Vtama | $58 | 2 payments
|
| Janssen Biotech | Tremfya | $42 | 2 payments
|
| Arcutis Biotherapeutics | Zoryve | $39 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $34 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $30 | 1 payment
|
| Pfizer | Eucrisa | $25 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $18 | 1 payment
|
2023: $146
| Abbvie | Rinvoq | $73 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $30 | 1 payment
|
| Abbott Laboratories | Xience Sierra | $23 | 1 payment
|
| Kerecis | Kerecis Omega3 Surgiclose | $20 | 1 payment
|
2022: $279
| Lilly USA | Taltz | $129 | 5 payments
|
| Novartis Pharmaceuticals | Cosentyx | $86 | 1 payment
|
| Abbvie | Skyrizi | $45 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $19 | 1 payment
|
2021: $82
| Regeneron Healthcare Solutions | Dupixent | $39 | 2 payments
|
| Lilly USA | Taltz | $22 | 1 payment
|
| AbbVie | Humira | $21 | 1 payment
|
2020: $121
| AbbVie | Skyrizi | $80 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $23 | 1 payment
|
| Genzyme | Dupixent | $19 | 1 payment
|
2019: $41
| Pfizer | Chantix | $41 | 3 payments
|
Professional record
- NPI
- 1124514682
- Licence
- CA A191911, IN 01082871ACalifornia A191911: Current · expires 2027-11-30
- Trained
- Temple University School of Medicine, 2018 · 8 years ago
- Group
- Csi Medical Group
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); General practice (208D00000X); Student in a training program (390200000X)
- Mailing address
- 100 E Lancaster Ave, Wynnewood, PA, 19096
- NPI first listed
- 2018-07-09
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9781 Blue Larkspur Ln, Monterey, CA, 93940 · 136 N San Mateo Dr Fl 2, San Mateo, CA, 94401